Purpose: Dendritic cell (DC)-based vaccines are limited by the short persistence of MHC class I/peptide complexes on the DC surface—often only a few hours—when soluble peptides are loaded exogenously. This short presentation limits CTL activation and vaccine efficacy. The authors investigated biodegradable PLGA microspheres (PLGA-MS) as an antigen delivery system to human monocyte-derived DC (hMoDC), aiming to prolong antigen presentation on both MHC class I and class II and improve DC-based immunotherapy.
Hypothesis: If protein or peptide antigens are encapsulated in PLGA microspheres and taken up by immature hMoDC, then antigen presentation via MHC class I and class II will be prolonged compared with soluble antigen, without adversely affecting critical DC functions such as migration, cytokine secretion, survival, or allostimulation.
Aims: Review the properties of PLGA-MS as an adjuvant and antigen delivery system. - Summarize data on direct vaccination of mice with PLGA-MS. - Assess whether PLGA-MS-mediated antigen delivery to DC leads to prolonged antigen presentation in vitro. - Evaluate whether PLGA-MS uptake affects pivotal functional properties of human monocyte-derived DC. - Discuss future strategies to improve PLGA-MS as an adjuvant for DC-based vaccination.
Delivery system:
Feature: Polymer; Description: Poly(D,L-lactide-co-glycolide) (PLGA/PLG)
Feature: Primary polymer used; Description: Resomer® RG502H: ~14 kDa, ~50% glycolate / 50% lactate, relatively hydrophilic, almost completely degraded in water within ~30 days
Feature: Particle type; Description: Microspheres (PLGA-MS)
Feature: Particle sizes; Description: 1.5–7 μm by spray drying; 10–100 μm by coacervation
Feature: Payloads; Description: Proteins and peptides: tetanus toxoid (TT), influenza matrix protein M1, Plasmodium antigens, malarial CTL peptide Pb252–260
Feature: Targeting ligand; Description: None
Feature: Application; Description: Antigen delivery to dendritic cells as cellular vaccines; direct vaccination in mice
Approach: This is a review article summarizing the authors’ own work and related literature.
- In vitro model: Human monocyte-derived DC (hMoDC) prepared under serum-free conditions; immature and mature hMoDC; mouse macrophages; antigen-specific CTL lines and T helper cell lines.
- In vivo model: Mice immunized subcutaneously with PLGA-MS containing TT or malarial peptides; comparisons with Alum and incomplete Freund’s adjuvant (IFA).
- Readouts: Antibody titers and isotypes, T cell proliferation, CTL cytolytic activity, antigen presentation kinetics, DC surface phenotype, cytokine secretion, allostimulation, and migration.
- Group structure / controls: Comparisons between soluble antigen and PLGA-MS-encapsulated antigen; untreated DC controls; maturation controls with LPS or proinflammatory cytokines.
Key methods: Flow cytometry for quantitative uptake of fluorescent PLGA-MS by hMoDC. - Phase contrast microscopy for visualization of phagocytosed microspheres. - CTL cytolytic assays for MHC class I-restricted antigen presentation. - T cell proliferation assays for MHC class II-restricted presentation. - Antibody titer and isotype measurements after mouse immunization. - Surface marker staining for CD80, CD83, CD86, HLA-DR, HLA-A2, and MMR. - Cytokine ELISA for IL-12, IL-10, and TNF-α. - Transwell migration assays toward CCL19 and CCL21. - In vivo migration of mouse bone-marrow-derived DC to draining lymph nodes.
Key results: Uptake: Immature hMoDC took up 10–30 PLGA-MS per cell within 1–4 h; 61% of cells were FITC-MS positive by flow cytometry. - Direct vaccination: A single injection of 20 µg TT in PLGA-MS yielded antibody titers equivalent to three injections of TT in Alum-3 with boosters at 5 and 14 weeks; IgG1, IgG2a, and IgG2b titers were similar, with no prominent IgE switch. - CTL induction: Specific CTLs to the malarial peptide Pb252–260 were detected after a single round of restimulation; lysis was similar for IFA and PLGA-MS. - MHC class I presentation: Soluble M1 peptide-loaded hMoDC stimulated CTL for only 4 days, whereas PLGA-MS-encapsulated peptide still stimulated CTL at 7–9 days. - MHC class II presentation: Soluble TT required 100 ng/mL for T helper proliferation, while PLGA-MS TT required only 10 ng/mL—a 10-fold lower antigen dose. Presentation lasted 10 days with PLGA-MS vs. 6 days with soluble TT. - DC function: PLGA-MS uptake did not alter surface markers (CD80, CD83, CD86, HLA-DR), did not induce maturation by itself, and did not impair maturation with LPS or cytokines. Allostimulation, cytokine secretion (IL-12, IL-10, TNF-α), and migration toward CCL19/CCL21 were unaffected. In vivo mouse DC migration to draining lymph nodes was also unaffected.
Interpretation: The authors conclude that PLGA-MS antigen delivery to DC markedly prolongs MHC class I- and class II-restricted antigen presentation without harming critical DC functions, and therefore has potential to improve the efficacy of DC-based cancer immunotherapy. They suggest that PLGA-MS may also serve as a direct vaccine adjuvant, but note that clinical translation requires solutions for sterilization and, likely, co-encapsulation of DC maturation stimuli or chemoattractants.
Limitations: This is a review, not a primary systematic study; several key data points are unpublished. - Evidence is mainly from in vitro hMoDC and mouse models; no clinical trial data are presented. - Sterilization is problematic: γ-irradiation alters PLGA-MS release properties and may destroy encapsulated antigens; aseptic GMP production is costly. - PLGA-MS alone did not induce DC maturation; immature DC can suppress rather than stimulate CTL responses, so maturation stimuli are likely required. - The approach relies on autologous DC generation, which is labor-intensive and expensive for routine clinical use. - No large-animal validation or long-term survival data are included.
